Clinical Trial Update: A Study to Assess Use of Zenapax (Daclizumab) and CellCept (Mycophenolate Mofetil) to Improve Kidney Function in Kidney Transplant Patients [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating the combination of Zenapax (daclizumab) and CellCept (mycophenolate mofetil) to improve kidney function in kidney transplant patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Zenapax (daclizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED